secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2024-06-14T23:59:59+00:00
Accession:  0001104659-24-071801
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics prices $11M public offering of common stock and pre-funded warrants
--------------------------------------------------------------------------------

- Offering of 7,116,547 shares at $1.35/share and 1,031,602 pre-funded warrants at $1.3499 each.
- Gross proceeds of ~$11M; net proceeds of ~$10.1M after discounts and expenses.
- Proceeds to fund clinical development of GT-02287 for GBA1 Parkinson's disease.
- Underwriter Titan Partners granted 30-day option for 1,222,222 additional shares (15% over-allotment).
- Underwriter warrants for 570,370 shares at $1.6875, exercisable 6 months post-closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000110465924071801/0001104659-24-071801-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000110465924071801/tm2416858d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-071801

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer